Share on StockTwits

Seattle Genetics (NASDAQ:SGEN) CEO Clay B. Siegall unloaded 11,200 shares of the stock in a transaction dated Tuesday, August 12th. The stock was sold at an average price of $40.38, for a total value of $452,256.00. Following the transaction, the chief executive officer now directly owns 525,217 shares in the company, valued at approximately $21,208,262. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Shares of Seattle Genetics (NASDAQ:SGEN) traded up 2.31% during mid-day trading on Wednesday, hitting $41.60. The stock had a trading volume of 902,889 shares. Seattle Genetics has a 52 week low of $32.35 and a 52 week high of $55.99. The stock’s 50-day moving average is $36.9 and its 200-day moving average is $41.30. The company’s market cap is $5.135 billion.

Seattle Genetics (NASDAQ:SGEN) last issued its quarterly earnings data on Thursday, July 31st. The company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.09. The company had revenue of $68.30 million for the quarter, compared to the consensus estimate of $65.04 million. During the same quarter in the previous year, the company posted ($0.06) earnings per share. The company’s revenue for the quarter was down 7.2% on a year-over-year basis. Analysts expect that Seattle Genetics will post $-0.81 earnings per share for the current fiscal year.

Seattle Genetics, Inc is biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for cancer.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.